Evidence map›Paper›PMID 31884486›Full record

ArticleJournal of Alzheimer's disease : JAD2020

Predicting Amyloid-β Levels in Amnestic Mild Cognitive Impairment Using Machine Learning Techniques.

Ali Ezzati, Danielle J Harvey, Christian Habeck, Ashkan Golzar, Irfan A Qureshi, Andrea R Zammit, Jinshil Hyun, Monica Truelove-Hill, Charles B Hall, Christos Davatzikos and 2 more

Open access · greenAbstract read
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 38 citations in OpenAlex.

  1. Yonsei medical journal · 2022
    Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Contributions of the ADNI Biostatistics Core.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Observational
  14. Predicting amyloid-beta pathology in the general population.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023
    Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Ali EzzatiDepartment of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA.
Danielle J HarveyDepartment of Public Health Sciences, University of California-Davis, Davis, CA, USA.
Christian HabeckCognitive Neuroscience Division, Department of Neurology, Columbia University, New York, NY, USA.
Ashkan GolzarElement AI, Montreal, Quebec, QC, Canada.
Irfan A QureshiDepartment of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA.
Andrea R ZammitDepartment of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA.
Jinshil HyunDepartment of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA.
Monica Truelove-HillBiohaven Pharmaceuticals, New Haven, CT, USA.
Charles B HallElement AI, Montreal, Quebec, QC, Canada.
Christos DavatzikosBiohaven Pharmaceuticals, New Haven, CT, USA.
Richard B LiptonDepartment of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA.
Alzheimer’s Disease Neuroimaging Initiative
Albert Einstein College of Medicine · USBiohaven Pharmaceuticals (United States) · USColumbia University · USMontefiore Medical Center · USUniversity of California, Davis · US

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
Vascular Structure and Function in Cognitive AgingP01AG003949 · NIA · YESHIVA UNIVERSITY · PI CAROL A. DERBY · 1985 to 2026
$73.9M
Role of impaired cognitive states & risk factors in conversion to mixed dementiasR01AG038651 · NIA · UNIVERSITY OF KENTUCKY · PI ABNER, ERIN, KRYSCIO, RICHARD J. · 2011 to 2023
$6.1M
Stress, Unconstructive Repetitive Thought and Cognitive AgingR01AG039409 · NIA · PENNSYLVANIA STATE UNIVERSITY, THE · PI SLIWINSKI, MARTIN J · 2011 to 2015
$2.5M
Predictive analytics for cognitive decline and Alzheimer’s diseaseK23AG063993 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI EZZATI, ALI · 2020 to 2024
$984k
Application of latent and integrative approaches to understand the spectrum of cognitive agingK01AG054700 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI ZAMMIT, ANDREA ROSE · 2017 to 2021
$653k
NIA NIH HHS K01 AG054700NIA NIH HHS K23 AG063993NIA NIH HHS P01 AG003949NIA NIH HHS R01 AG038651NIA NIH HHS R01 AG039409NIA NIH HHS U01 AG024904
6 · The paper itself

Abstract

backgroundAmyloid-β positivity (Aβ+) based on PET imaging is part of the enrollment criteria for many of the clinical trials of Alzheimer's disease (AD), particularly in trials for amyloid-targeted therapy. Predicting Aβ positivity prior to PET imaging can decrease unnecessary patient burden and costs of running these trials.

objectiveThe aim of this study was to evaluate the performance of a machine learning model in estimating the individual risk of Aβ+ based on gold-standard of PET imaging.

methodsWe used data from an amnestic mild cognitive impairment (aMCI) subset of the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort to develop and validate the models. The predictors of Aβ status included demographic and ApoE4 status in all models plus a combination of neuropsychological tests (NP), MRI volumetrics, and cerebrospinal fluid (CSF) biomarkers.

resultsThe models that included NP and MRI measures separately showed an area under the receiver operating characteristics (AUC) of 0.74 and 0.72, respectively. However, using NP and MRI measures jointly in the model did not improve prediction. The models including CSF biomarkers significantly outperformed other models with AUCs between 0.89 to 0.92.

conclusionsPredictive models can be effectively used to identify persons with aMCI likely to be amyloid positive on a subsequent PET scan.

Indexed as

Machine LearningAgedAllelesAmyloid beta-PeptidesApolipoprotein E4BiomarkersBrainCognitive DysfunctionFemaleGene FrequencyHumansMagnetic Resonance ImagingMaleMiddle AgedNeuroimagingNeuropsychological TestsAmyloid beta-PeptidesApolipoprotein E4BiomarkersAlzheimer’s diseaseamyloid imagingmachine learningmild cognitive impairmentpredictive analytics

Identifiers

PMID31884486
PMCPMC7376527
OpenAlexW2997795833

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.